| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
|
Medicine details |
|
| Medicine name | sacubitril valsartan (Entresto®) |
| Formulation | 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg film-coated tablet |
| Reference number | 686 |
| Indication | In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/11/2015 |
| NICE guidance | |